Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

C21H24FN3O4.HCl

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

91 API Suppliers, 24 USDMF, 24 CEP/COS, 7 JDMF, 16 EU WC, 17 KDMF, 18 NDC API, 48 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

134 FDF Dossiers, 31 FDA Orange Book, 68 Europe, 13 Canada, 2 South Africa, 20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 Rochem International Inc, 7 SPI Pharma, 9 DKSH, 1 Pharm-RX Chemical, 5 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 3 Kirsch Pharma, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 12 BASF, 1 CD Formulation, 2 Clariant, 10 Corel Pharma Chem, 1 Curia, 6 DFE Pharma, 1 Esteem Industries, 1 Finar, 10 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures, 4 Ingredion Pharma Solutions, 21 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 27 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

59 Fillers, Diluents & Binders, 48 Coating Systems & Additives, 28 Disintegrants & Superdisintegrants, 26 Thickeners and Stabilizers, 24 Controlled & Modified Release, 24 Direct Compression, 22 Solubilizers, 21 Lubricants & Glidants, 20 Film Formers & Plasticizers, 20 Granulation, 19 Parenteral, 18 Topical, 14 Co-Processed Excipients, 12 Taste Masking, 10 Chewable & Orodispersible Aids, 10 Rheology Modifiers, 9 Emulsifying Agents, 8 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 19 News #PharmaBuzz

GLOBAL SALES INFORMATION

19 US Medicaid Prescriptions, 4 Regulatory FDF Prices, 4 Annual Reports

MARKET PLACE

29 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 18 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 2 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Dr. Reddy\'s Laboratories	India	Hanareum Farm Co., Ltd.	20201211-209-J-529(2)	Moxifloxacin hydrochloride	2021-02-05	Dr. Reddy's Laboratories Limited	India	Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri Venkateswara Co-operative Industrial Estate Bollaram Village, Jinnaram Mandal, Sangareddy District, Telangana, 502325 INDIA
29/11/2025	Enaltec Labs	India	Essel Bio Co., Ltd.	20221012-209-J-1378(1)	Moxifloxacin hydrochloride	2023-04-12	Enaltec Labs Private Limited	India	Plot no. 825, 826 & 827, Sector-III, Industrial Area, Dist-Dhar, Pithampur-454 774, Madhya Pradesh, India

C21H24FN3O4.HCl

C21H24FN3O4.HCl

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

91 API Suppliers

24 USDMF

24 CEP/COS

7 JDMF

16 EU WC

17 KDMF

18 NDC API

48 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

6 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

134 FDF Dossiers

31 FDA Orange Book

68 Europe

13 Canada

2 South Africa

20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 400MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION/DROPS;OPHTHALMIC - EQ 0.5% BASE

RELATED EXCIPIENT COMPANIES

1 Minakem

2 Rochem International Inc

7 SPI Pharma

9 DKSH

1 Pharm-RX Chemical

5 Boai NKY Pharmaceuticals Ltd

8 Gangwal Healthcare

6 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

3 Kirsch Pharma

1 ACG Worldwide

8 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

12 BASF

1 CD Formulation

2 Clariant

10 Corel Pharma Chem

1 Curia

6 DFE Pharma

1 Esteem Industries

1 Finar

10 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

5 Ideal Cures

4 Ingredion Pharma Solutions

21 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

11 Microlex e.U

1 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

3 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

27 Roquette

13 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

TABLET;ORAL - EQ 400MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOLUTION;INTRAVENOUS - 400MG/250ML (1.6MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons